127 related articles for article (PubMed ID: 12695169)
61. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.
Kowalzick L; Bertolini J; Baumann C; Walther B; Truhm B; Eickenscheidt L
J Dtsch Dermatol Ges; 2013 May; 11(5):447-9. PubMed ID: 23343137
[No Abstract] [Full Text] [Related]
62. Psoriatic arthritis: biologics seen as new treatment. More aggressive treatment is recommended for psoriatic arthritis, a severe, progressive form of the disease.
Duke Med Health News; 2012 Apr; 18(4):7. PubMed ID: 22545278
[No Abstract] [Full Text] [Related]
63. Evaluating the real-world benefits and risks of anti-tumor necrosis factor therapies.
Low A; Hyrich K
J Rheumatol; 2013 Jan; 40(1):4-6. PubMed ID: 23280161
[No Abstract] [Full Text] [Related]
64. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.
Spadaro A; Riccieri V; Sili-Scavalli A; Sensi F; Taccari E; Zoppini A
Clin Exp Rheumatol; 1995; 13(5):589-93. PubMed ID: 8575136
[TBL] [Abstract][Full Text] [Related]
65. Disseminated Salmonella typhimurium infection secondary to infliximab treatment.
Fu A; Bertouch JV; McNeil HP
Arthritis Rheum; 2004 Sep; 50(9):3049. PubMed ID: 15457476
[No Abstract] [Full Text] [Related]
66. Psoriatic arthritis treated with cyclosporin A.
Kokelj F; Lavaroni G; Stinco G
Allerg Immunol (Paris); 1992 Dec; 24(10):393-4. PubMed ID: 1288546
[TBL] [Abstract][Full Text] [Related]
67. Psoriasis onset during infliximab treatment: description of two cases.
Volpe A; Caramaschi P; Carletto A; Pieropan S; Bambara LM; Biasi D
Rheumatol Int; 2006 Oct; 26(12):1158-60. PubMed ID: 16738903
[TBL] [Abstract][Full Text] [Related]
68. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
[TBL] [Abstract][Full Text] [Related]
69. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study.
Atzeni F; Boccassini L; Antivalle M; Salaffi F; Sarzi-Puttini P
Ann Rheum Dis; 2011 Apr; 70(4):712-4. PubMed ID: 20810394
[No Abstract] [Full Text] [Related]
70. Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs.
Spadaro A; Taccari E; Mohtadi B; Riccieri V; Sensi F; Zoppini A
Clin Exp Rheumatol; 1997; 15(6):609-14. PubMed ID: 9444416
[TBL] [Abstract][Full Text] [Related]
71. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
72. Acute injection site reaction to intraarticular etanercept administration.
Arnold EL; Khanna D; Paulus H; Goodman MP
Arthritis Rheum; 2003 Jul; 48(7):2078-9. PubMed ID: 12847708
[No Abstract] [Full Text] [Related]
73. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
[TBL] [Abstract][Full Text] [Related]
74. Erythema nodosum, a "red flag" during anti-TNF therapy.
Dalmau-Carolà J
Int J Rheum Dis; 2013 Aug; 16(4):493-4. PubMed ID: 23992277
[No Abstract] [Full Text] [Related]
75. International consensus recommendations on cyclosporin use in rheumatoid arthritis.
Tugwell P
Drugs; 1995; 50 Suppl 1():48-56. PubMed ID: 8714799
[TBL] [Abstract][Full Text] [Related]
76. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.
Bergman M; Lundholm A
Arthritis Res Ther; 2017 Mar; 19(1):63. PubMed ID: 28320454
[TBL] [Abstract][Full Text] [Related]
77. Psoriatic arthritis. Is something changing?
Scarpa R
Adv Exp Med Biol; 1999; 455():207-14. PubMed ID: 10599345
[TBL] [Abstract][Full Text] [Related]
78. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
[TBL] [Abstract][Full Text] [Related]
79. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
80. Opioids can paradoxically induce severe pain.
Berthelot JM; Nizard J; Maugars Y
Joint Bone Spine; 2018 Dec; 85(6):655-657. PubMed ID: 29729433
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
